Becton, Dickinson and Company (BDX)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Becton, Dickinson and is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- The stock has been climbing and sits near the top of its range for the year.
- Worth watching
- Its growth over the past year trails most other healthcare companies.
Analyst price target
~12-month · 13 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments…
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 72,000
- Headquarters
- Franklin Lakes, NJ
Similar stocks
What’s behind the score
Valuation
P/E 44.6 — lower than 14% of Healthcare peers
P/B 2.1 — lower than 75% of Healthcare peers
P/S 2.3 — lower than 73% of Healthcare peers
EV/EBITDA 11.2 — lower than 70% of Healthcare peers
EV/Revenue 3.0 — lower than 73% of Healthcare peers
PEG 1.1 — lower than 74% of Healthcare peers
FCF yield 8.6% — higher than 97% of Healthcare peers
Profitability & quality
Gross margin 46.9% — higher than 33% of Healthcare peers
Operating margin 15.7% — higher than 33% of Healthcare peers
Net margin 4.2% — higher than 27% of Healthcare peers
ROE 6.6% — higher than 26% of Healthcare peers
ROA 4.3% — higher than 24% of Healthcare peers
Free cash flow is 272% of reported net income
Financial health
Debt/equity 0.7 — lower than 44% of Healthcare peers
Current ratio 0.86 — higher than 14% of Healthcare peers
Quick ratio 0.33 — higher than 3% of Healthcare peers
Cash/debt 0.04 — higher than 7% of Healthcare peers
Debt/EBITDA 2.75 — lower than 31% of Healthcare peers
Growth
Revenue growth 5.4% YoY — higher than 27% of Healthcare peers
Earnings growth -31.4% YoY — higher than 15% of Healthcare peers
Ownership & investor activity
Payout ratio 72.5% — atypical vs Healthcare peers
Net insider buying, +7.5% of insider shares
Institutions net sold, -20.0% of shares held
Insiders hold 0.4% of shares outstanding
4.1% of float sold short
Momentum
Above its 50- & 200-day averages
94% of the way from its 52-week low to high